Zhitong Finance App News, Hengrui Pharmaceutical (01276.HK) announced that recently, the company's subsidiary Suzhou Shengdia Biomedical Co., Ltd.'s injectable Ruikang Luzetolatamab (injectable SHR-A2009) was included in the list of breakthrough treatment varieties by the Drug Evaluation Center of the China Drug Administration.

Zhitongcaijing · 2d ago
Zhitong Finance App News, Hengrui Pharmaceutical (01276.HK) announced that recently, the company's subsidiary Suzhou Shengdia Biomedical Co., Ltd.'s injectable Ruikang Luzetolatamab (injectable SHR-A2009) was included in the list of breakthrough treatment varieties by the Drug Evaluation Center of the China Drug Administration.